Cue Biopharma, Inc.
NASDAQ:CUE
Overview | Financials
Company Name | Cue Biopharma, Inc. |
Symbol | CUE |
Currency | USD |
Price | 1.52 |
Market Cap | 91,515,704 |
Dividend Yield | 0% |
52-week-range | 0.45 - 3.249 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Daniel R. Passeri J.D., M.Sc., MSc. |
Website | https://www.cuebiopharma.com |
An error occurred while fetching data.
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD